Pharmaceutical industry: A one-stop resource

EU additional monitoring list for medicines


Welcome to the pharmaceutical industry area of the MHRA website. This section, which has been developed following feedback from users, provides targeted links to information throughout the site, as well as content relevant to the industry.

If you have any feedback on this section and how we can improve it please email webusability@mhra.gsi.gov.uk or fill out our feedback form.

There is a link at the top of every page of the MHRA website which links directly to this section.


News and hot topics

Man reading news on a computer - home

16 May 2013 | Changes to medicines names: sulphate to sulfate

Further to the nomenclature harmonisation in 2003/04 Changes to medicines names: BANs to rINNs, the European Pharmacopoeia and British Pharmacopoeia have amended the spelling of sulphate to sulfate for all products containing sulfate (or sulfur containing compounds eg sulfonate).

25 Apr 2013 | EU additional monitoring list for medicines

The Pharmacovigilance Risk Assessment Committee (PRAC) has published the European so-called ‘mandatory’ list of medicines under additional monitoring.

14 Mar 2013 | Guidance on submitting label and leaflet mock-ups following variations

In April 2012, following consultation with medicines trade associations and member companies we announced some procedural changes concerning the requirement to submit full-colour mock-ups of labels and patient leaflets. In the last year we have received a number of requests for a copy of the guidance, which we have now published on our website.

14 Mar 2013 | Joint BIA/MHRA Conference: Innovation in the development and regulation of biopharmaceuticals

The third joint BIA and MHRA conference will focus on supporting innovation in the development and regulation of biopharmaceuticals from both regulatory and life sciences industry perspectives.

11 Mar 2013 | Press release: MHRA launches an ‘Innovation Office’ to encourage the development of novel medical products and devices

The MHRA is launching an ‘Innovation Office’ to help organisations who are developing innovative medicines, medical devices or using novel manufacturing processes to navigate the regulatory processes in order to be able to progress their products or technologies.

The unwanted display of the text is removed here...dont delete this

Fees

Invoice - home
This page includes the fees payable for the regulation of medicines, guidance for periodic fees, and how to make payments to the MHRA.
The unwanted display of the text is removed here...dont delete this

Clinical trials

Clinical trials - home
This page provides links to information on applying for a clinical trial authorisation (CTA), maintaining a CTA, safety reporting and  Good Clinical Practice (GCP).
The unwanted display of the text is removed here...dont delete this

Post marketing authorisation approval

Box of pils - home
This page provides links to information about post marketing authorisation approval procedures, including  variations, renewals, and changes of ownership.
The unwanted display of the text is removed here...dont delete this

Herbal, homeopathic and borderline medicines

Herbal and homeopathic - home
This page provides links to information on how to place a herbal medicine on the UK market, homeopathic medicines and borderline medicines.
The unwanted display of the text is removed here...dont delete this

Manufacturing and wholesaling

Man standing by a pile of boxes - home
This page provides links to information about manufacturer's and wholesale dealer's licences, including the registers of licensed sites and lists of  new, terminated and revoked licences, importing and exporting, and the associated legislation and guidance.
The unwanted display of the text is removed here...dont delete this

Contacting the MHRA

Contacting the MHRA - home
This page provides links to information about how to contact the MHRA. It also includes an escalation procedure for industry to resolve any issues informally.

Legislation, guidance and policy

Legislation, guidance and policy - home
This page provides links to information on medicines legislation, guidance and policy. It includes an overview of medicines legislation, including preparing a medicinal product for sale in the UK or EU marketplace, how the MHRA develops policy, and current MHRA consultations relevant to industry.

Applying for a marketing authorisation

Post marketing authorisation approval - home
This page provides links to all the information needed for obtaining a marketing authorisation (including parallel import licences) in the UK.

Product information and advertising

Woman reading a patient information leaflet - home
This page provides links to information on product information (labels, patient information leaflets and packaging) and advertising.

Inspection

Inspection - home
This page provides links to information about the different types of inspection, including the inspection process and risk-based inspections, as well as the associated legislation and guidance.

Safety and pharmacovigilance

Safety and pharmacovigilance - home
This page provides links to information about safety and pharmacovigilance, including adverse drug reaction reporting, periodic safety update reports, 'Drug Safety Update', as well as the associated legislation and guidance.

Over-the-counter medicines

Medicine being sold over the counter - home
This page provides links to the latest information about over-the-counter (OTC) medicines including products containing codeine, pseudoephedrine and children's cough and cold medicines and reclassification of medicines, as well as questions and answers on the new OTC Product Licensing Assessment Team (PLAT) 7.

Medicines for children

Mother giving medicine to her child - home
This page provides links to information about the regulation of medicines for children, including the requirements for submission of paediatric data and the European paediatric work-sharing procedures.
Page last modified: 25 April 2013